Microbot Medical Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Microbot Medical Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 91% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.2 times its market value (net cash). Higher than 91% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 751% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 89% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-257.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 91% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-44.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 70% of Healthcare companies in United States.
Cash Cushion Ratio
1.2× cashCash, after subtracting all debt, is 1.2 times its market value (net cash).
Higher than 91% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Microbot Medical Inc. made a loss over the last year. Microbot Medical Inc. owes $0.05 for every $1 it owns. Microbot Medical Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMicrobot Medical Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.85The share price is 0.85 times Microbot Medical Inc.'s book value per share, lower than 82% of Healthcare companies in United States.
Market cap
$63 MThe total market value of all of Microbot Medical Inc.'s shares at today's price (share price × number of shares), smaller than 71% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$74 MWhat Microbot Medical Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$1.10Net worth divided by the number of shares. The share price of $0.94 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-32.9%Microbot Medical Inc. lost 32.9% of its shareholders' money over the last year, higher than 59% of Healthcare companies in United States.
Owes vs Owns
0.05×Microbot Medical Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Dividend yield
NoneMicrobot Medical Inc. does not currently pay a dividend.
Profit growth
LossMicrobot Medical Inc. made a loss in each of the last two years.
Cash vs debt
Net cashMicrobot Medical Inc. held $78 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Microbot Medical Inc.: $63 M ÷ $74 M (31 Mar 2026) = 0.9.
What is Microbot Medical Inc.'s return on equity?
Microbot Medical Inc. lost 32.9% of its shareholders' money over the last year, higher than 59% of Healthcare companies in United States.
How much does Microbot Medical Inc. owe compared with what it owns?
Microbot Medical Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Does Microbot Medical Inc. pay a dividend?
No. Microbot Medical Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.